E
Erasca, Inc. (ERAS)
NMS – Real vaqt narxi. Valyuta: USD
16.01
+1.06 (7.09%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
16.10
+0.09 (0.54%)
Bozordan keyin: Jun 26, 2026, 7:56 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
16.01
+1.06 (7.09%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
16.10
+0.09 (0.54%)
Bozordan keyin: Jun 26, 2026, 7:56 PM EDT
Erasca, Inc., klinik bosqichdagi aniq onkologiya kompaniyasi, RAS/MAPK yo'li bilan boshqariladigan saraton kasalliklari bo'lgan bemorlar uchun terapiyalarni kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning mahsulot qatoriga RAS mutatsiyali qattiq o'smalari bo'lgan bemorlarni davolash uchun pan-RAS molekulyar yopishqoq ERAS-0015; KRAS mutatsiyali qattiq o'smalari bo'lgan bemorlarni davolash uchun pan-KRAS ingibitori ERAS-4001; va EGFR va RAS/MAPK qattiq o'smalarini davolash uchun tadqiqotdagi EGFR D2/D3 biparatopik antikorp (bpAb) ERAS-12 kiradi. U Guangzhou Joyo Pharmatech Co., Ltd bilan ma'lum pan-RAS ingibitorlarini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha; Medshine Discovery Inc. bilan ma'lum pan-KRAS ingibitorlarini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha; Novartis Pharma AG bilan naporafenibni ishlab chiqish, ishlab chiqarish, ishlatish va tijoratlashtirish bo'yicha; NiKang Therapeutics, Inc. bilan ERAS-601 va boshqa tegishli birikmalarni ishlab chiqish va tijoratlashtirish bo'yicha; va Asana BioSciences, LLC bilan ERAS-007 va boshqa tegishli birikmalarni ishlab chiqish va tijoratlashtirish bo'yicha litsenzion kelishuvga ega. Kompaniya ERAS-0015ni baholash uchun Tango Therapeutics, Inc. bilan klinik sinov hamkorligi va ta'minot shartnomasiga ega. Erasca, Inc. 2018-yilda ro'yxatga olingan va shtab-kvartirasi San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David M. Chacko M.D. | CFO & Chief Business Officer |
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman & CEO |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Dr. Michael D. Varney Ph.D. | Chairman of Research & Development, Scientific Advisory Board Member and Director |
| Dr. Nik Chetwyn Ph.D. | Chief Operating Officer |
| Dr. Robert Shoemaker Ph.D. | Chief Scientific Officer |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer |
| Mr. Brian L. Baker CPA, M.S. | Senior Vice President of Finance |
| Mr. Ebun S. Garner Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Alison Tjosvold Milhous | Senior Vice President of Accounting |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 8-K | eras-20260511.htm |
| 2026-05-11 | 10-Q | eras-20260331.htm |
| 2026-04-28 | DEFA14A | d946335ddefa14a.htm |
| 2026-04-28 | DEF 14A | d946333ddef14a.htm |
| 2026-04-28 | ARS | d947850dars.pdf |
| 2026-04-27 | 8-K | eras-20260427.htm |
| 2026-04-21 | 8-K | eras-20260421.htm |
| 2026-03-12 | 8-K | eras-20260312.htm |
| 2026-03-12 | 10-K | eras-20251231.htm |
| 2026-01-29 | 8-K | eras-20260129.htm |